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Abstract Fibromyalgia is a clinical syndrome that currently
does not have any specific pathological finding to aid in
diagnosis. Therefore, fibromyalgia is most likely a heteroge-
neous group of diseases with similar symptoms. Identifying
and understanding the pathological basis of fibromyalgia will
allow physicians to better categorize patients, increasing pro-
spective treatment options, and improving potential therapeu-
tic endeavors. Recent work has demonstrated that approxi-
mately 50 % of patients diagnosed with fibromyalgia have
damage to their small unmyelinated nerve fibers. A skin
punch biopsy is a sensitive and specific diagnostic test for this
damage as a reduction in nerve fiber density allows for the
diagnosis of small fiber neuropathy. Small fiber neuropathy is
a disease with symptoms similar to fibromyalgia, but it often
has a definable etiology. Identifying small fiber neuropathy
and its underlying cause in fibromyalgia patients provides
them with a succinct diagnosis, increases treatment options,
and facilitates more specific studies for future therapeutics.
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Introduction
Fibromyalgia (FM) is the second most commonly diagnosed
rheumatic disorder and is prevalent in 2 to 8 % of the popu-
lation [1–3]. FM has been described as a clinical syndrome
without any specific pathological findings to confirm a diag-
nosis. The diagnosis of FM is particularly challenging as it
commonly presents as a constellation of ill-defined symptoms
producing a heterogeneous group of diseases with similar
complaints [4]. To add to the challenge, the most recent
diagnostic criteria for FM mandates excluding all other disor-
ders that could account for the pain [1].
For many patients, FM is a lifelong disorder, which many
sufferers describe as being in a state of chronic pain. Although
the centralized nature of the pain implies that it originates in,
or is amplified by, the central nervous system, it does not rule
out peripheral nociceptor input as a contributing factor to the
pain. In fact, FM patients may experience more pain than
typically expected from the contributing nociceptive input
[3]. The subjective and non-specific symptoms of FM make
the diagnosis and treatment a challenge for the clinician,
which undoubtedly leads to frustration for patients. In addi-
tion, patients who experience neuropathic symptoms often do
not receive the most accurate diagnosis or appropriate treat-
ment. This lack of validation of their symptoms leads to
further stress [3].
While FM is a syndrome with unidentifiable causes and
pathophysiology, small fiber neuropathy (SFN) is a well-
defined disorder with an identifiable pathogenesis and distinct
underlying causes [4–7]. Symptoms of SFN usually present
distally, manifesting as foot or leg pain. As SFN advances, the
symptoms can spread proximally and involve the torso as well
[4]. Typical symptoms of SFN include paresthesia, allodynia,
hyperesthesia, and numbness. Patients usually describe these
sensations as painful, using terms such as burning or shooting.
SFN patients often exhibit decreased pinprick sensation,
hyperalgesia, or reduced thermal sensation in affected areas.
However, sensory examination can be entirely normal in
patients with SFN [5]. Additionally, skin changes of the
affected area such as shiny skin or decreased moisture of the
skin surface that leads to crackingmay also be observed [4, 6].
Nerve fibers vary in size and function, with large myelin-
ated A-alpha and A-beta fibers transmitting signals for pro-
prioception and touch, while small myelinated A-delta fibers
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and unmyelinated C fibers transmit signals for pain and tem-
perature. SFN is caused by dysfunction and degeneration of
the small unmyelinated C fibers and the thinly myelinated A-
delta fibers [4]. The most frequent underlying cause of SFN is
diabetes mellitus [8, 9], with other causes including impaired
glucose tolerance, vitamin deficiency (especially B12), hepa-
titis C virus, human immunodeficiency virus, vasculitis, celiac
disease, Sjorgen’s syndrome and other autoimmune condi-
tions, hematological malignancies, infections, toxins (alcohol,
medications), and genetic mutations [5–8]. These various
conditions cause deterioration of the small nerves under the
skin, leaving them damaged or dead, which then results in
transmission of abnormal signals, and ultimately produces the
burning or shooting pain associated with SFN [5, 8, 10, 11].
Despite clear pathophysiology and known etiologies, diag-
nosis of SFN in patients with pure SFN (no damage to the
large nerve fibers) is challenging because motor coordination,
reflexes, light touch, proprioception, and vibratory sensation
often appear normal during examination [6]. Although phys-
ical examination and medical history of the patient have been
the gold standard used to diagnose SFN, ancillary testing may
provide added guidance. Some of the available tools for
testing have included the neuropathic pain inventory, quanti-
tative sensory testing (QST), quantitative sudomotor axon
reflex testing (QSART), electromyography, and nerve con-
duction studies. Additionally, another diagnostic technique
that has recently become widely and commercially available
is the skin punch biopsy, which is used to measure epidermal
nerve fiber density (ENFD) [6].
FM/SFN diagnosis
Previously, the American College of Rheumatology (ACR)
diagnostic criteria (1990) for FMwas based on the presence of
widespread pain and tender points [12]. However, this defini-
tion of FMwas controversial as changes in the amount of pain
or number of tender points could vary over time, causing
patients previously diagnosed with FM to no longer qualify
for a FM classification [1, 13]. In 2010, the ACR updated the
FM criteria based on the Widespread Pain Index (WPI) and
Symptoms Severity Scale [SS; [1]]. However, neither of these
diagnostic criteria included any objective testing, forcing most
clinicians to rely on subjective clinical complaints to diagnose
their FM patients. Due to the subjective diagnostic criteria,
unknown causes, and non-specific symptoms, many clinicians
consider FM to be a collection of ill-defined illnesses. SFN is
one such condition that, in the absence of an established
objective diagnostic test, had been placed under the generic
diagnosis of FM. Patients with SFN have complaints of tin-
gling, burning, and pain, which often is not recognized as a
distinct condition and continues to bemisinterpreted as FM. In
many cases, the patients’ symptoms are symmetrical,
persistent, and length-dependent, resemblingmixed-fiber neu-
ropathy. However, some patients experience symptoms that
are non-length-dependent such as inconsistent numbness that
is multifocal [11]. With the most prominent symptom of SFN
being only the “burning” pain, many patients describe no
unique feature to distinguish SFN from other disorders. Diag-
nosis of SFN, therefore, occurs largely by means of exclusion
[7] similar to FM as evidenced by one of the main criteria for
diagnosis of FM being ‘lack of a disorder that could explain
the pain’ [1]. Although some clinicians utilize multiple diag-
nostic tests for the diagnosis of neuropathic pain, many tests
have limited sensitivity and specificity for SFN. The physio-
logical characteristics of small nerve fibers make diagnosis
with electrophysiological tests particularly difficult [5]. There-
fore, it is not surprising that diagnostic testing using electro-
myography and nerve conduction studies were found to be
predominantly insensitive for SFN [4].
To fill in the void of objective diagnostics for SFN, the skin
bunch biopsy technique was developed at the Karolinska
Institute and later standardized at the University of Minnesota
and at Johns Hopkins University. These punch biopsies began
to be included in the diagnostic workup of patients with
suspected SFN after the identification of antibodies against
protein gene product 9.5 (PGP 9.5). PGP 9.5 is a neuronal
form of ubiquitin carboxyl-terminal hydrolase transported
with the slow component of the axonal transport. The avail-
ability of this antibody enabled visualization of the extensive
innervation of the epidermis [5, 14] and the capacity for
quantitation of epidermal innervation by small fibers [9]. This
skin biopsy test was so specialized, however, that it remained
solely in research hands for many years. It requires skilled and
highly trained pathologists to process the sample and perform
the very detailed task of manually counting the nerve fibers. It
has, however, recently become commercially available at
many academic centers and a few specialized labs in the
USA. Each lab has its own established cutoff values for ENFD
(lab norms), which allow the practitioners to make a diagnosis
of SFN with greater certainty [15]. The convenience and ease
of modern day shipping methods have made this test readily
available to clinicians all over the country.
Over the past few years, skin punch biopsy testing has
emerged as a diagnostic standard for SFN. This diagnostic
procedure is recommended in practice guidelines for the di-
agnosis of SFN by both American and European task forces
[10, 15]. The European Federation of Neurological Societies
has provided a level A recommendation for the use of skin
biopsy to measure the density of small fiber epidermal inner-
vation [15]. Additionally, an American Polyneuropathy Task
Force also recommended the use of skin biopsy in the evalu-
ation of polyneuropathies, which include SFN [10]. The joint
task force guideline report, published in 2010, updated their
guidelines to include skin punch biopsies in the diagnosis of
SFN, noting that, based on the vast experience of skin punch
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biopsies in 10 established laboratories worldwide, the 3-mm
skin punch biopsy technique is a safe and minimally invasive
procedure [15]. Major side effects have not been reported with
the skin punch biopsy. Only 2 side effects were reported, the
first being mild infections, often resulting from improper
wound management which resolved easily with topical anti-
biotic therapy. Excessive bleeding from the punch biopsy was
the only other side effect reported, which resolved without the
need of a suture [15].
One of the key benefits of the skin biopsy test is its
effectiveness in assessing SFN when compared to other diag-
nostic tests, such as electromyography and nerve conduction
studies. The test can also be repeatedmultiple times tomonitor
disease progression or treatment efficacy [16]. Specificity and
sensitivity reported for the skin punch biopsy vary from 88 to
92 % [15]. Another benefit of early skin biopsy testing for
SFN in FM patients is that patients and their clinicians can
have objective evidence explaining the origin of the symp-
toms. Understanding the pathological basis for the patient’s
neuropathic symptoms will allow clinicians to categorize pa-
tients more effectively. In addition, an accurate diagnosis of
SFN can prompt an in-depth assessment to uncover any
underlying diseases as a possible root cause of the patient’s
symptoms. Table 1 provides a list of evaluations that may be
performed to determine the underlying etiology of SFN in
these patients [17]. Identifying the underlying etiology of SFN
can also lead to better treatment plans, testing for new and
more effective treatment choices, and promoting research to
develop new therapeutics. Incorporating the skin biopsy test
as a routine evaluation for all FM patients may be beneficial in
diagnosing SFN in approximately 50 % of patients. Because
the skin biopsy test can reliably demonstrate the loss of
epidermal nerve fibers, it can not only confirm the diagnosis
of SFN when clinical and neurophysiologic examinations are
not adequately informative but also indicate progression of the
disease by observing the reduction of ENFD over time with
repeated skin biopsies [15].
Clinical relevance and utility of skin punch biopsy
In a case-controlled study, 25 FM patients were com-
pared with 55 healthy controls matched for gender and
age. This study demonstrated a quantitative reduction in
epidermal innervation and regeneration sparing myelin-
ated nerve fibers in FM patients [17]. Participants
underwent punch biopsies from 2 regions of the leg.
For the lower leg biopsy, the median ENFD was
5 fibers/mm in FM patients, compared to 9.5 fibers/
mm in the healthy controls. Similarly, for the biopsy
sample from the upper thigh, the median ENFD for FM
patients was 8.0 fibers/mm compared to the control
group with 11.6 fibers/mm. Utilizing the skin biopsy
technology, the investigators were able to objectively
demonstrate the loss of nerve fibers in some FM pa-
tients [18].
Another case-controlled study published in 2013 examined
25 FM patients and 30 gender- and age-matched controls [4].
In this study, participants were evaluated with the autonomic
function test (AFT) and the skin punch biopsy. Punch biopsies
of 2 to 3 mm in diameter were collected from the standard
distal leg site of the participants. The study results revealed
that 50 % of the FM subjects and only 17 % of the control
subjects had one or more of the objective test results that
revealed SFN (p<0.001). In this study, skin biopsy results
alone demonstrated that 41 % of FM subjects had ENFD in
the <5th percentile of predicted lab norms, in comparison to
3 % of control subjects (p<0.001). The investigators propose
that their findings suggest that some FM patients with neuro-
pathic pain could have undiagnosed SFN [4].
More recently, a prospective study of 20 FM patients and
32 age-matched, healthy controls found that 40 % of patients
with neuropathic-like symptoms demonstrated decreased
ENFD [19]. Another 2014 study of 41 FM patients and 47
healthy controls demonstrated significantly decreased ENFD
in FM patients in the calf (5.8 vs 7.4 fibers/mm; p=0.0002)
and thigh (9.3 vs 11.3 fibers/mm; p=0.0007) compared to
controls [20].
Finally, a retrospective study of 56 FM patients evaluated at
specialized peripheral neuropathy centers found reduced
ENFD in 61 % of the subjects [18]. Additionally, laboratory
evidence for underlying causes of SFN was found for 71 % of
the patients with decreased ENFD [18].
Table 1 Potential causes of small fiber neuropathy and related testing





2-h glucose tolerance, HgbA1c





Vitamin B12 deficiency B-12, methylmalonic acid,
homocysteine







ACE angiotensin converting enzyme, ANA anti-nuclear antibody, ANCA
anti-neutrophil cytoplasmic antibody, HgbA1c hemoglobin A1c, HIV
human immunodeficiency virus
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Feasibility of skin punch biopsy
The skin punch biopsy is an easy procedure that can be
performed in a doctor’s office by the physician, nurse practi-
tioner, or physician’s assistant. This procedure causes minimal
pain and discomfort to the patient requiring no sutures, only an
adhesive bandage. The procedure is found to be easier than an
electromyogram nerve conduction study that is routinely per-
formed to diagnose neuropathic conditions. The skin biopsy
test is a medically necessary and approved test that is fully
recognized by the American Academy of Neurology. It is no
longer an experimental procedure and is billable and reim-
bursable through the majority of commercial carriers and
Medicare. The ease, speed, and convenience of modern ship-
ping options also make skin punch biopsy testing a feasible
option for clinicians.
The utility of punch biopsy in FM has been further validat-
ed by a retrospective chart review, which revealed a change in
treatment plans in 36 of 69 (52 %) patients after a punch
biopsy was performed [21]. Having an accurate diagnosis will
make a drastic difference to those patients who have been told
that their symptoms have no pathophysiological explanation.
Knowing that their skin biopsy revealed a reduced ENFD
gives patients an objective and scientific validation of their
symptoms. Therefore, it is imperative that skin biopsy be a
fundamental part of the routine diagnostic workup of FM,
especially in patients with symptoms suggestive of SFN such
as burning, stabbing, tingling, and allodynia, in contrast to the
typical deep muscular and aching pain seen in FM [4, 18–20].
Conclusion
Previous studies have demonstrated that approximately 50 %
of patients diagnosed with FM may have SFN contributing to
their sensory and autonomic symptoms [4, 17, 18], indicating
that the measurement of ENFD is an essential step in evaluat-
ing FM patients and excluding other treatable causes of their
pain. The skin punch biopsy is a simple, reliable, and defini-
tive diagnostic test that is currently available for the measure-
ment of ENFD for these patients [10, 15]. The biopsy can be
performed in any physician’s office and shipped at room
temperature to one of the few specialized labs that performs
this type of testing. The results give physicians an objective
diagnostic tool to fulfill the diagnostic criteria for FM by
excluding SFN as a cause of their patients’ pain [1] and may
allow for the detection of any underlying etiology and ulti-
mately provide appropriate treatment and a possible cure for
some of these SFN patients [22]. The skin punch biopsy
procedure is no longer an experimental test, it is endorsed by
the major neurology and neuropathy associations nationally
and internationally, making it reimbursable by most insurance
carriers. It is also easily performed in the clinic with minimal
discomfort to the patient. The benefits of accurate diagnosis
and the ease of testing make the skin punch biopsy an integral
part of diagnostic testing for SFN among FM patients.
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